Turnstone Biologics Corp. (TSBX)
Aug 11, 2025 - TSBX was delisted (reason: acquired by XOMA)
0.3550
0.00 (0.00%)
Inactive · Last trade price
on Aug 8, 2025
Company Description
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California.
Turnstone Biologics Corp.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 21, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Sammy Farah |
Contact Details
Address: 9310 Athena Circle, Suite 300 San Diego, California 92037 United States | |
| Phone | 347 897 5988 |
| Website | turnstonebio.com |
Stock Details
| Ticker Symbol | TSBX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001764974 |
| CUSIP Number | 90042W100 |
| ISIN Number | US90042W1009 |
| Employer ID | 83-2909368 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sammy J. Farah M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Saryah Azmat | Consultant |
| Wendy Worcester CFA, CPA | Vice President, Principal Finance and Accounting Officer |
| Dr. David Stojdl Ph.D. | Senior Vice President of Research and Discovery |
| Dr. Ines Verdon M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | SCHEDULE 13D/A | Filing |
| Aug 11, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 11, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 11, 2025 | 8-K | Current Report |
| Aug 11, 2025 | SC 14D9/A | Filing |
| Aug 11, 2025 | 25-NSE | Filing |
| Aug 11, 2025 | SC TO-T/A | Filing |
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Jul 24, 2025 | SC TO-T/A | Filing |
| Jul 17, 2025 | SC 14D9/A | Filing |